Method for prevention of colectomy
The present invention relates to methods of preventing or reducing the need of colectomy. In particular, the present invention relates to an oligonucleotide, for use in the treatment of an inflammatory bowel disease, such as ulcerative colitis (UC) or Crohn's disease, in a subject that is refractory or responds insufficiently or is intolerant to anti-inflammatory therapy, wherein said oligonucleotide is repetitively administered as a single exposure.
1. A method of treating chronic active ulcerative colitis in a subject that is refractory or responds insufficiently or is intolerant to anti-inflammatory therapy, comprising administering to a patient in need thereof, an effective exposure of an oligonucleotide comprising the sequence 5′-GGAACAGTTCGTCCATGGC-3′ (SEQ ID NO:2) and wherein at least one CG dinucleotide is unmethylated, wherein individual doses of said oligonucleotide are administered on two or more separate occasions 4 or more weeks apart.
2. The method of claim 1 , wherein at least one nucleotide in said oligonucleotide has a backbone modification.
3. The method of claim 2 , wherein said backbone modification is a phosphate backbone modification represented by a phosphorothioate or a phosphorodithioate modification.
4. The method of claim 3 , wherein said phosphate backbone modification is located in the 5′- and/or the 3′-end of said oligonucleotide.
5. The method of claim 1 , wherein said oligonucleotide has the sequence 5′-G*G*A*ACAGTTCGTCCAT*G*G*C-3′ (SEQ ID NO:1), wherein the CG dinucleotide is unmethylated.
6. The method of claim 1 , wherein said two or more separate occasions are 4 to 8 weeks apart.
7. The method according to claim 1 , wherein individual doses of said oligonucleotide are administered on three separate occasions 4 weeks apart.
8. The method of claim 1 , wherein individual doses of said oligonucleotide are administered on two separate occasions 4 weeks apart.
9. The method of claim 1 , wherein the amount of each individual dose of said oligonucleotide is in the range from about 0.3 mg to about 100 mg.
10. The method of claim 1 , wherein the amount of each individual dose of said oligonucleotide is in the range from about 25 mg to about 60 mg.
11. The method of claim 1 , wherein the amount of each individual dose of said oligonucleotide is about 30 mg.
12. The method of claim 1 , wherein said composition is administered as an add-on to a current therapy.
13. The method of claim 1 , wherein said oligonucleotide is administered topically to mucosal membranes.
14. The method of claim 1 , wherein said oligonucleotide is administered intracolonically.
15. The method of claim 1 , wherein said subject is elective for colectomy.
16. The method of claim 15 , wherein said colectomy is prevented or delayed.
17. A method of treating chronic active ulcerative colitis in a subject that is refractory or responds insufficiently or is intolerant to anti-inflammatory therapy, the method comprising: administering to the subject an oligonucleotide comprising the sequence 5′-GGAACAGTTCGTCCATGGC-3′ (SEQ ID NO:2), wherein at least one CG dinucleotide is unmethylated, and wherein individual doses of 30 mg each of the oligonucleotide are administered on two or more separate occasions 4 or more weeks apart.